How is ER Low Used in Clinical Trials?
Clinical trials are studying the response of ER low tumors to hormone therapy. Visit the links to learn more.
The Latest Research on CDK 4/6 Inhibitors
Learn about new CDK 4/6 inhibitor research in different breast cancer subtypes, including HER2+ and triple-negative MBC.
Triple-Negative Metastatic Breast Cancer: Beyond ER, PR, and HER2
Click to learn about biomarkers and targeted therapies for triple-negative MBC.
Bispecific Antibodies: An Emerging Class Of MBC Drugs
Learn about bispecific antibodies, which bind to two targets instead of one, for MBC treatment.
Metastatic Breast Cancer News from 2021 ESMO
Click here for MBC-related research and reports from ESMO 2021.
Metastatic Breast Cancer News from ASCO 2021
Click here for MBC-related research and reports from ASCO 2021.
St. Gallen International Breast Cancer Conference 2021
Learn about the current research on HR-positive, HER2-Positive, Triple-Negative MBC, and other MBC subtypes from the 2021 St. Gallen International Breast Cancer Conference.
2021 Update on Metastatic Triple Negative Breast Cancer Treatment
Treatment options for triple negative breast cancer are increasing. Learn about what’s available now and what’s being studied in clinical trials.